Patients with Major Depressive Disorder (MDD) Get Earlier Access to a Not-yet-registered Medicine
|| Print ||
|Friday, 20 December 2013 08:30 (UTC + 1)|
Not-yet-registered transdermal MAO inhibitor available via myTomorrows
Amsterdam, the Netherlands, December 20, 2013 / B3C newswire / – The online patient platform myTomorrows will offer patients access to an antidepressant medicine from the UK based company Syntropharma Ltd. It concerns a MAO inhibitor that is continuously released in low dosages via a transdermal patch on the skin. Transdermal MAO inhibitors have been registered and approved for the treatment of MDD in the United States for several years.
Although depression is one of the most expensive medical conditions in healthcare, it remains a very stigmatized an underestimated health issue. People with MDD are severely limited in their social engagement and participation in family life and society. Furthermore they have higher risks of developing additional physical conditions like cardiovascular diseases. The MAO inhibitor that is available via myTomorrows could be an alternative for patients with MDD who don’t respond to existing antidepressants.
Sjaak Vink, CEO of myTomorrows, comments “I’m very pleased that myTomorrows offers patients who suffer from MDD and their Psychiatrists a treatment alternative that could better their daily lives. Family members who also suffer from the effects of this disease shouldn’t be forgotten. Their situation is often underestimated.”
Andrew Gardiner, CEO of Syntropharma Ltd, adds “This agreement with myTomorrows underlines our commitment to create early access to our innovative medicines for patients in need and we’re pleased that patients can actually benefit from our collaboration.”
myTomorrows makes this investigational medicine available within the scope of the existing early access legislation. On Psychiatrist’s request the medicine will be supplied as soon as possible in The Netherlands, Belgium Luxembourg, France, Italy, Germany and Turkey.
About Syntropharma Ltd
Contact Syntropharma Ltd